Replies to post #9392 on Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

So as I read it, '113

1. Blocks EGFR as well as ALK,

2. Will be in a "Phase 1/2" trial (I assume that's phases 1 & 2 rather than phase 0.5), and

3. Won't start in the clinic until Q3 -- which is a bit of a delay IIRC, but the idea is that we will have a much more compelling trial.